ArticleApplied biochemistry and biotechnology2025
Transcription Factor TCF12 Activates the Transcription Level of SLC38A1 to Promote the Development of Hepatocellular Carcinoma.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The impact of metabolic reprogramming in hepatocellular carcinoma on T cell.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a primary liver cancer with a high mortality rate. The pathogenic mechanism of HCC is complex. In this study, we aimed to explore the functions of Solute Carrier Family 38 Member 1 (SLC38A1) and transcription factor 12 (TCF12) in HCC malignancy. Immunohistochemistry (IHC) assay was performed to estimate the expression of SLC38A1 in HCC. qRT-PCR assay and western blot assay were conducted to determine the expression of SLC38A1, TCF12, epithelial-mesenchymal transition (EMT)-related markers and ferroptosis-related markers. Colony formation assay and EdU assay were utilized to evaluate cell proliferation ability. Transwell assay was employed for cell migration and invasion. Reactive oxygen species (ROS), glutathione (GSH), malondialdehyde (MDA), and iron levels were examined with related kits. ChIP assay and dual-luciferase reporter assay were performed to verify the relationship between TCF12 and SLC38A1. The in vivo experiment was conducted to assess the function of TCF12 in vivo. SLC38A1 was upregulated in HCC tissues and cells. SLC38A1 knockdown suppressed HCC cell proliferation, migration, invasion, and EMT and inhibited ferroptosis in vitro. The transcription factor TCF12 could activate the transcription level of SLC38A1. TCF12 overexpression ameliorated the effects of SLC38A1 knockdown on HCC cell malignant behaviors. Moreover, TCF12 silencing inhibited tumorigenesis in vivo. TCF12 targeted SLC38A1 to promote HCC cell proliferation, migration and invasion and restrained ferroptosis, providing a novel sight for HCC pathogenesis.
Indexed as
Identifiers
40478369What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.